Drug
Tesetaxel clinical trials
Also written DJ-927.
- studies test it
- 16
- open now
- 0
- in phase 3
- 1
- first study started
- 2004
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
16 studies that test it; most in 2010 (6)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2010 | 6 |
| 2011 | 4 |
| 2012 | 2 |
| 2017 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 11
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 1
Genta Incorporated (11) · Daiichi Sankyo (2) · Odonate Therapeutics, Inc. (2) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tesetaxel is read from its arms, and is right about nine times in ten.
Testing it · 16
- Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBCTerminatedPhase 3Odonate Therapeutics, Inc.NCT03326674Written as Tesetaxel and Capecitabine
- Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBCTerminatedPhase 2Odonate Therapeutics, Inc.NCT03858972Written as Tesetaxel
- Phase II Study of Tesetaxel in Metastatic MelanomaCompletedPhase 2M.D. Anderson Cancer CenterNCT01064713Written as Tesetaxel
- Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg CapsulesCompletedPhase 1Genta IncorporatedNCT01170975Written as Tesetaxel 10 mg with and then without food
- A Study of Tesetaxel Plus Capecitabine in Patients With Solid TumorsStatus unknownPhase 1Genta IncorporatedNCT01315431Written as Tesetaxel plus capecitabine
- Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric CancerStatus unknownPhase 2Genta IncorporatedNCT01573468Written as Tesetaxel
- Tesetaxel as First-line Therapy for Metastatic Breast CancerStatus unknownPhase 2Genta IncorporatedNCT01221870Written as Tesetaxel once every 3 weeks
- Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate CancerStatus unknownPhase 2Genta IncorporatedNCT01296243Written as Tesetaxel
- Tesetaxel for Previously Treated Patients With Bladder CancerStatus unknownPhase 2Genta IncorporatedNCT01215877Written as Tesetaxel
- Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast CancerStatus unknownPhase 2Genta IncorporatedNCT01609127Written as Tesetaxel
- DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal AdenocarcinomaCompletedPhase 2Daiichi SankyoNCT00080834Written as DJ-927
- DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1Daiichi SankyoNCT00077077Written as DJ-927
- Tesetaxel as Second-line Therapy for Patients With Advanced Gastric CancerStatus unknownPhase 2Genta IncorporatedNCT01095120Written as Tesetaxel
- Study of Tesetaxel in Japanese Patients With Solid TumorsStatus unknownPhase 1Genta IncorporatedNCT01337310Written as Tesetaxel
- Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric CancerStatus unknownPhase 1/2Genta IncorporatedNCT01348009Written as Tesetaxel-capecitabine-cisplatin
- Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDHStatus unknownPhase 2Genta IncorporatedNCT01092585Written as Tesetaxel
Given in every arm · 2 — tesetaxel is usual care beside what is tested
- Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBCTerminatedPhase 2Odonate Therapeutics, Inc.NCT03952325Written as Tesetaxel
- The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid TumorsTerminatedPhase 1Odonate Therapeutics, Inc.NCT04312282Written as Tesetaxel
Codes
What other systems call tesetaxel · ClinicalTrials.gg INT004591
- MeSH (NLM) C479543tesetaxelOne source NLM
- UNII (FDA) UG97LO5M8YTESETAXELConfirmed FDA, NLM, Wikidata
- Wikidata Q7705452tesetaxelConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C37451TesetaxelOne source FDA
- DrugBank DB12019One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C479543 | tesetaxel | One source NLM |
| UNII (FDA) | UG97LO5M8Y | TESETAXEL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7705452 | tesetaxel | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C37451 | Tesetaxel | One source FDA |
| DrugBank | DB12019 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.